Marc G Achen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4211254/publications.pdf

Version: 2024-02-01

53 papers	8,130 citations	117571 34 h-index	206029 48 g-index
54 all docs	54 docs citations	54 times ranked	7163 citing authors

#	Article	IF	Citations
1	Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. Communications Biology, 2021, 4, 878.	2.0	6
2	Evolutionary Differences in the Vegf/Vegfr Code Reveal Organotypic Roles for the Endothelial Cell Receptor Kdr in Developmental Lymphangiogenesis. Cell Reports, 2019, 28, 2023-2036.e4.	2.9	23
3	The evolving role of lymphatics in cancer metastasis. Current Opinion in Immunology, 2018, 53, 64-73.	2.4	88
4	Emerging Roles for VEGF-D in Human Disease. Biomolecules, 2018, 8, 1.	1.8	125
5	Exit Stage Left: A Tumor Cellâ€™s Journey from Lymph Node to Beyond. Trends in Cancer, 2018, 4, 519-522.	3.8	7
6	A Three-Dimensional Lymphatic Endothelial Cell Tube Formation Assay to Identify Novel Kinases Involved in Lymphatic Vessel Remodeling. Assay and Drug Development Technologies, 2017, 15, 30-43.	0.6	6
7	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. Science Signaling, 2017, 10, .	1.6	37
8	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 621.	2.2	132
9	Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature Reviews Cancer, 2014, 14, 159-172.	12.8	621
10	Exploring the role of endothelium in the tumour response to anti-angiogenic therapy. Biochemical Society Transactions, 2014, 42, 1569-1575.	1.6	6
11	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. Molecular Therapy, 2014, 22, 18-27.	3.7	112
12	Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 409-425.	1.7	13
13	Vascular Endothelial Growth Factor-d Modulates Caliber and Function of Initial Lymphatics in the Dermis. Journal of Investigative Dermatology, 2013, 133, 2074-2084.	0.3	36
14	The Propeptides of VEGF-D Determine Heparin Binding, Receptor Heterodimerization, and Effects on Tumor Biology. Journal of Biological Chemistry, 2013, 288, 8176-8186.	1.6	25
15	Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 149-161.	0.8	7
16	Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. Growth Factors, 2012, 30, 283-296.	0.5	32
17	VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium. Cancer Cell, 2012, 21, 181-195.	7.7	244
18	The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway. Oncotarget, 2012, 3, 893-906.	0.8	47

#	Article	IF	Citations
19	Lymphangiogenesis in Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2009, , .	0.1	1
20	Lymphangiogenesis in Health and Disease â€“ An Overview. Cancer Metastasis - Biology and Treatment, 2009, , 1-9.	0.1	0
21	Molecular Control of Lymphatic Metastasis. Annals of the New York Academy of Sciences, 2008, 1131, 225-234.	1.8	229
22	Sox18 induces development of the lymphatic vasculature in mice. Nature, 2008, 456, 643-647.	13.7	483
23	Proprotein convertases promote processing of VEGFâ€Ð, a critical step for binding the angiogenic receptor VEGFRâ€². FASEB Journal, 2007, 21, 1088-1098.	0.2	100
24	Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and Metastasis. American Journal of Pathology, 2007, 170, 1348-1361.	1.9	119
25	A system for quantifying the patterning of the lymphatic vasculature. Growth Factors, 2007, 25, 417-425.	0.5	36
26	Tumor lymphangiogenesis and metastatic spreadâ€”New players begin to emerge. International Journal of Cancer, 2006, 119, 1755-1760.	2.3	126
27	Growth factors and lymphangiogenesis. , 2006, , 53-74.		0
28	Focus on lymphangiogenesis in tumor metastasis. Cancer Cell, 2005, 7, 121-127.	7.7	291
29	Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System. Molecular and Cellular Biology, 2005, 25, 2441-2449.	1.1	232
30	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. Clinical Cancer Research, 2004, 10, 5137-5144.	3.2	102
31	Lymphangiogenic growth factors as markers of tumor metastasis. Apmis, 2004, 112, 539-549.	0.9	64
32	Plasmin activates VEGF-C and VEGF-D. International Congress Series, 2004, 1262, 79-82.	0.2	1
33	Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D. Journal of Experimental Medicine, 2003, 198, 863-868.	4.2	184
34	VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses. Circulation Research, 2003, 92, 1098-1106.	2.0	374
35	Vascular Endothelial Growth Factor D (VEGF-D). , 2003, , 559-564.		0
36	The role of tumor lymphangiogenesis in metastatic spread. FASEB Journal, 2002, 16, 922-934.	0.2	264

#	Article	IF	Citations
37	Adenovirus encoding vascular endothelial growth factorâ€“D induces tissue-specific vascular patterns in vivo. Blood, 2002, 99, 4434-4442.	0.6	102
38	The Angiogenic and Lymphangiogenic Factor Vascular Endothelial Growth Factor-D Exhibits a Paracrine Mode of Action in Cancer. Growth Factors, 2002, 20, 99-107.	0.5	54
39	Molecular control of lymphangiogenesis. BioEssays, 2002, 24, 1030-1040.	1.2	90
40	The vascular endothelial growth factor family; proteins which guide the development of the vasculature. International Journal of Experimental Pathology, 2002, 79, 255-265.	0.6	105
41	Lymphangiogenesis and cancer metastasis. Nature Reviews Cancer, 2002, 2, 573-583.	12.8	729
42	Inhibitors of Angiogenesis. , 2002, , 261-292.		0
43	Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. Journal of Pathology, 2001, 193, 147-154.	2.1	130
44	Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO Journal, 2001, 20, 1223-1231.	3.5	583
45	VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Medicine, 2001, 7, 186-191.	15.2	1,113
46	The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. Journal of Biological Chemistry, 2001, 276, 19166-19171.	1.6	152
47	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. FEBS Journal, 2000, 267, 2505-2515.	0.2	101
48	VEGFâ€C and VEGFâ€D expression in neuroendocrine cells and their receptor, VEGFRâ€3, in fenestrated blood vessels in human tissues. FASEB Journal, 2000, 14, 2087-2096.	0.2	299
49	A Mutant Form of Vascular Endothelial Growth Factor (VEGF) That Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability. Journal of Biological Chemistry, 1999, 274, 34884-34892.	1.6	96
50	Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers. Journal of Biological Chemistry, 1999, 274, 32127-32136.	1.6	281
51	The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development. Growth Factors, 1999, 17, 1-11.	0.5	52
52	Placenta Growth Factor and Vascular Endothelial Growth Factor are Co-Expressed During Early Embryonic Development. Growth Factors, 1997, 15, 69-80.	0.5	70
53	The Lymphatics: On the Route to Cancer Metastasis. , 0, , 237-254.		0